Trial Profile
A Phase 1/2a study of CNP520 for Alzheimer's Disease.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Oct 2016
Price :
$35
*
At a glance
- Drugs Umibecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2016 New trial record